Marcus had tried everything. Eighteen months of sertraline, then venlafaxine, then three augmentation strategies, two courses of cognitive therapy, and one catastrophic course of electroconvulsive therapy that left him unable to remember his sister's name for six weeks. At 41, he had become a medical oxymoron: a person with treatment-resistant depression who had exhausted the treatable. His psychiatrist mentioned psilocybin almost reluctantly, half an apology wrapped in clinical language. That conversation happened in early 2025. By February 2026, Marcus was one of the first patients in the world to receive the synthesized, proprietary formulation now bearing the clinical name COMP360, under the controlled conditions of a Phase 3 trial. He described the experience as "the first time in eleven years my brain went quiet."
That quiet is the thing researchers have been chasing for two decades.
The Scale of the Problem Nobody Wants to Talk About
Depression is not a niche affliction. According to World Health Organization data from 2021, approximately 332 million people worldwide live with the condition. That number is so large it loses meaning in casual conversation, but it translates to roughly one in every 24 people on the planet. The economic and human cost is staggering in ways that compound: lost productivity, strained relationships, shortened lifespans. For most patients, the first antidepressant works. For a significant minority, it does not.
The clinical threshold for treatment-resistant depression, or TRD, is typically defined as failure to respond to two or more adequate courses of antidepressant medication. By that measure, nearly 30 percent of patients with major depressive disorder qualify. These are the people cycling through the pharmacy drawer of half-working pills, the ones who attend therapy and practice the techniques and still cannot get out of bed on Wednesday. Standard protocols offer little beyond medication roulette and increasingly invasive interventions. The pipeline for novel antidepressants has been, by any honest accounting, disappointing. Most new formulations in recent decades have been variations on monoaminergic themes, tweaking the same neurotransmitter systems that existing drugs already target.
This is the gap COMP360 is designed to fill.
What Makes Psilocybin Different
Psilocybin is the psychoactive compound found in certain fungi, but COMP360 is not a mushroom in any meaningful sense. It is a synthetically produced, proprietary formulation of psilocybin developed by Compass Pathways, designed to pharmaceutical standards of purity, dose, and reproducibility. The molecule is the same, but the context is entirely clinical: controlled dosing, structured psychological support, trained facilitators, and a six-to-eight hour supervised session in a specially designed room.
The mechanism of action is where psilocybin departs most dramatically from conventional antidepressants. Most antidepressants work by increasing synaptic concentrations of serotonin, dopamine, or norepinephrine, a brute-force neurochemical approach that requires daily dosing and often blunts emotional range along with the depression. Psilocybin, by contrast, acts primarily on the 5-HT2A serotonin receptor, but its downstream effects are considerably more complex. Functional neuroimaging studies have consistently shown that psilocybin produces a pronounced reduction in default mode network activity. This network, sometimes described as the brain's background noise system, is hyperactive in depression, maintaining a chronic loop of rumination, self-referential processing, and negative bias. Disrupting that loop, even temporarily, appears to allow the brain an opportunity to reorganize around different patterns.
The Phase 2b trial published by Goodwin and colleagues in 2023 remains the landmark study. It enrolled 233 participants, all of whom had failed at least two previous antidepressant trials, making it the largest randomised controlled clinical trial of psilocybin ever conducted at the time [1]. Participants were randomised to receive a single dose of 25 milligrams, 10 milligrams, or 1 milligram of COMP360, the latter serving as the control. All sessions were accompanied by psychological support from two trained therapists. The results, published in the Journal of Affective Disorders, showed that the 25-milligram dose produced statistically significant improvements in depression severity as measured by the MADRS scale, the standard psychiatric rating tool. For a population that had exhausted conventional options, even a single-dose signal was striking.
The Psychedelic Experience Itself
What makes the research particularly compelling is not just that psilocybin reduced depression scores, but why it might work. A 2025 analysis published in the Journal of Affective Disorders examined the relationship between the subjective psychedelic experience during treatment and clinical outcomes [2]. The researchers, led by Goodwin and Carhart-Harris, found that depression response correlated with specific dimensions of the psychedelic experience at all doses, but the correlations at the 25-milligram dose were the strongest.
Two scales stood out in particular. Oceanic Boundlessness, which measures ego dissolution and feelings of unity with the surrounding world, showed a correlation of r equals negative 0.508 with MADRS improvement at the 25-milligram dose. Visual Restructuralization, capturing changes in visual perception and the sense of meaning embedded in ordinary experience, correlated at r equals negative 0.516 [2]. The Emotional Breakthrough Inventory, which captures moments of emotional release, insight, and reconciliation with difficult experience, showed the strongest correlation of all at r equals negative 0.637 [2].
These are not trivial statistical associations. Correlation coefficients of this magnitude, at a single dose, in a population this severely ill, are unusual in psychiatric research. The intensity of the psychedelic effects was dose-related, and the dose-response relationship in subjective experience mirrored the dose-response relationship in clinical outcomes. The implication, which the researchers are careful to frame cautiously, is that the psychedelic experience itself may be part of the therapeutic mechanism, not a side effect to be managed.
Safety and the Antidepressant Discontinuation Question
One of the practical barriers to psilocybin treatment has been the requirement that patients discontinue existing antidepressants before dosing, a process that carries its own risks. A 2024 study published in the Journal of Psychiatric Research examined whether antidepressant discontinuation compromised treatment outcomes or increased suicidality in the COMP360 trial population [3].
The analysis, drawing on data from the same 233 participants, found that antidepressant discontinuation was not related to worsening depression severity before the baseline measurement. Suicidality scores were comparable between participants who had discontinued antidepressants and those who were antidepressant-free at baseline [3]. Perhaps most importantly, the efficacy of psilocybin treatment did not appear to be compromised by prior antidepressant use. This finding is significant because it removes one of the major clinical objections to psilocybin therapy: the danger of a medication-free window in a population with high baseline suicidality.
The Road to Approval
The FDA decision on COMP360 is expected at the end of 2026. Phase 3 trials are currently ongoing, and the first results released in February 2026 showed sufficient promise to keep the program moving forward. If approval comes, it will represent the first FDA-approved psychedelic antidepressant in American medicine, a category that did not exist six years ago.
The implications extend beyond the regulatory milestone. Psilocybin's mechanism appears to be fundamentally different from existing antidepressants, which means it may work in patients who have not responded to anything else. The single-dose format, if it holds up in Phase 3, would represent a dramatic departure from the daily pill regimen that defines current treatment. And the correlation between subjective experience and clinical outcome suggests that the therapy itself, not just the molecule, may be integral to how COMP360 works.
Not everyone will be a candidate. The population studied so far has been carefully selected, and real-world patients come with complexities that clinical trials struggle to capture. But for patients like Marcus, who have run through the entire existing catalogue of interventions, the arrival of a new mechanism of action is not merely a statistical event. It is the sound of a door opening that they had assumed was welded shut.